Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06651177 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

A Phase 2 study of Opioid Use Disorder and Opioid Use Disorder, Moderate, sponsored by T. John Winhusen, PhD.

Recruiting
Registry status
Phase 2
Development phase
310
Enrollment target
10
Study locations

NCT06651177 is a Phase 2 study of Opioid Use Disorder and Opioid Use Disorder, Moderate that is actively recruiting participants, run by T. John Winhusen, PhD. The registered enrollment target is 310 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06651177, a Phase 2 study of Opioid Use Disorder and Opioid Use Disorder, Moderate, is actively recruiting participants, sponsored by T. John Winhusen, PhD.

RECRUITING
Registry status
Phase 2
Development phase
310 participants
Enrollment target
10
Study locations

Study Summary

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

Conditions Studied

Opioid Use Disorder Opioid Use Disorder, Moderate Opioid Use Disorder, Severe

Interventions

  • DRUG Tirzepatide
  • OTHER Placebo

Study Locations (10)

Florida

  • Gateway Community Services - Jacksonville
  • IBIS Behavioral Health - Tampa

West Virginia

  • Marshall Health - Huntington
  • Healthy Minds/Chestnut Ridge - Morgantown

California

  • Tarzana Treatment Centers - Tarzana

Illinois

  • Ruth M. Rothstein CORE Center - Chicago

Missouri

  • The Gibson Center for Behavioral Change - Cape Girardeau

South Carolina

  • Prisma Health - Greenville

Tennessee

  • Vanderbilt University Medical Center - Nashville

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2025-12-12
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

T. John Winhusen, PhD

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06651177

The ClinicalTrials.gov registry entry for NCT06651177 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (93% lower). The listed sponsor is T. John Winhusen, PhD, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.

NCT06651177 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Florida, West Virginia, California.

Frequently Asked Questions

What is clinical trial NCT06651177 about?

NCT06651177 is a clinical study titled "Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder". The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

What is the current status of trial NCT06651177?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2025-12-12. Estimated completion is 2027-06-30.

What conditions does trial NCT06651177 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe.

What interventions are being tested in trial NCT06651177?

The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).

Who is sponsoring clinical trial NCT06651177?

This trial is sponsored by T. John Winhusen, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06651177 being conducted?

This trial has 10 study locations across California, Florida, Illinois, Missouri, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Opioid Use Disorder

All registered trials for this condition

Opioid Use Disorder, Moderate

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.